How to Buy Windtree Therapeutics Stock
Windtree Therapeutics Inc
Windtree Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases.
Windtree Therapeutics stock last closed at $1.13, down 0.88% from the previous day, and has decreased 99.57% in one year. It has underperformed other stocks in the Biotechnology industry by 0.22 percentage points. Windtree Therapeutics stock is currently +11.88% from its 52-week low of $1.01, and -99.85% from its 52-week high of $737.44.
At the moment, there are 3.56M shares of WINT outstanding. The market capitalization of WINT is $4.02M. In the past 24 hours, 65,606 WINT shares were traded.
How to Buy Windtree Therapeutics Stock
Not sure how to invest in Windtree Therapeutics stock? Here's how.
- Figure out where to buy Windtree Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Windtree Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your brokerage account: Pick your payment method and add your info.
- Evaluate Windtree Therapeutics stock: The Windtree Therapeutics ticker symbol is WINT. Is Windtree Therapeutics stock a good investment? Should you buy shares of WINT? How do WINT's underlying business fundamentals look? Do top analysts think Windtree Therapeutics is a good buy? Why has WINT's stock price moved recently? (Hint: Our stock research website can help you decide if WINT is a good stock to buy).
- Make your WINT purchase: Decide if you will purchase WINT shares at the current market price or use a limit order to purchase WINT stock at a particular price.
- Get the latest scoop on your WINT investment: Create a watchlist to track your new investment in Windtree Therapeutics shares.
Step 1: Figure out where to buy Windtree Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy WINT stock.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've picked the right brokerage, it's time to fill out some personal info so you are able to invest in WINT today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open your new brokerage account.
- Send your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've opened your account on the best stock buying app, you can securely and quickly fund your account:
Watch this video walkthrough to see the process of transferring funds into your investment account.
Step 4: Evaluate Windtree Therapeutics stock
After you have decided on the best place to buy Windtree Therapeutics stock, it's very important to analyze their stock prior to investing, so you truly wrap your head around the risk and upside.
Windtree Therapeutics Numbers
Windtree Therapeutics Due Diligence Checks
WallStreetZen was designed to help everyday investors perform more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on WINT's stock page.
Is WINT stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge WINT's true value.
Using relative valuations ratios:
- WINT could be undervalued based on its P/B ratio of 0.4x, relative to Biotechnology industry P/B ratio of 4.37x
You can access additional valuation analysis on WINT's stock here.
WINT Financials at a glance
Failed Health Checks:
- WINT has a relatively high debt to equity ratio of 1.47.
- Total WINT debt is higher than 5 years ago, relative to shareholder equity.
- WINT has $1.79M in cash and short term investments. This is not enough to cover its annual cash burn of $15.41M.
- There are more long-term liabilities than short-term assets on the WINT balance sheet.
- WINT has cash burn of 15414000. It does not have enough cash and short-term investments to cover this.
- There are more short-term liabilities than short-term assets on the WINT balance sheet.
Is it a good time to buy WINT stock, according to analysts?
Out of 1 sell side analysts who give ratings on WINT, the consensus analyst rating on Windtree Therapeutics is a Hold
It's important to note that analyst ratings are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Windtree Therapeutics stock forecast page.
WINT Technicals
WINT Performance Metrics
Last year, WINT revenue was $0.00. In the last five year, WINT's revenue has increased by -100% per year. This was slower than the Biotechnology industry average of 45.47%.
Dig into WINT's earnings and revenue performance here.
Latest Insiders Trades at WINT
Over the last 12 months, executives and large shareholders at WINT have bought more shares than they have sold.
Craig Fraser, President and CEO of WINT, was the latest WINT insider to buy. They bought $4,942.21 worth of WINT stock on Oct 8, 2024.
Research more about who owns WINT stock here.
Can I rely on WINT as an income stream?
No, Windtree Therapeutics doesn't provide an income stream by paying out dividends.
WINT Social Trading Data
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Make your WINT purchase
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly fine. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular price limit, place a limit order.
Press the Open button and your broker will place the order.
If you need more assistance buying stocks on eToro, watch the helpful video below:
Step 6: Get the latest scoop on your WINT investment
Now that you own some shares in WINT, you'll want to stay up-to-date on your new company.
Start a watchlist to track your WINT stock.
WINT Feed
How to Buy Stock in Windtree Therapeutics
To summarize, here are the 6 steps for buying Windtree Therapeutics stock:
- Figure out where to buy Windtree Therapeutics stock
- Sign up for a brokerage account
- Put funds into your brokerage account
- Evaluate Windtree Therapeutics stock
- Make your WINT purchase
- Get the latest scoop on your WINT investment
If you need a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep tabs on your new investment in Windtree Therapeutics, create a watchlist on WallStreetZen today.
More Articles You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.